EPZM - Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights and will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details of both events are as follows:

• Second Quarter 2020 Financial Results: Management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights on Tuesday, Aug. 4, 2020 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5081295.
• 2020 Wedbush PacGrow Healthcare Virtual Conference: Epizyme will participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, Aug. 11, 2020, with a company overview to be presented at 9:45 a.m. ET.

Live webcasts will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following each event.

About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK^® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.

TAZVERIK^® is a registered trademark of Epizyme, Inc. For full prescribing information, please visit TAZVERIK.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005262/en/